20년 동안 매수하고 보유할 나의 최고 AI 헬스케어 주식

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Markets LLY My Top AI Healthcare Stock to Buy and Hold for 20 Years January 26, 2026 — 07:25 am EST Written by Prosper Junior Bakiny for The Motley Fool -> Key Points Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its strong innovative capabilities. There are multiple reasons to hold the stock through the next 20 years. 10 stocks we like better than Eli Lilly › Artificial intelligence (AI) isn't just a gimmick or a fad. The technology is changing the lives of individuals, reshaping entire businesses and industries, and, by some estimations, the industry will grow rapidly in the coming years, providing investors with plenty of opportunities to capitalize by investing in top AI companies. While many (perhaps most) of the leaders in the field belong in the tech sector, corporations in other sectors, including healthcare, are looking to cash in on AI as well. And one of the best AI healthcare stocks to buy is none other than Eli Lilly (NYSE: LLY) . Here's why the company is worth sticking with through the next two decades. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Image source: Getty Images. Multiple AI initiatives Eli Lilly is doubling down on AI, far more than most of its similarly sized peers in its sector. Here are three moves the company has made. First, in September, it announced it was launching TuneLab, an AI drug discovery platform, and making it available for free to smaller biotech companies to help accelerate drug discovery. Many small drugmakers don't have the funds or data needed to train their own AI models, so that TuneLab will be useful to them. In exchange, they will provide Eli Lilly with even more data to train its own models. Then, in October, Eli Lilly announced it was partnering with Nvidia to build the most powerful AI supercomputer in the pharmaceutical industry . Finally, earlier this month, Eli Lilly announced it was building an AI drug discovery lab in the San Francisco Bay Area, also in partnership with Nvidia. This lab will bring together Eli Lilly's team of researchers and Nvidia's engineers to use AI to speed up drug discovery, a currently slow process. If Eli Lilly can succeed in cutting R&D spend and research time dedicated to developing blockbuster medicine thanks to these efforts, the company and its shareholders will benefit down the line. More reasons to buy Eli Lilly's AI initiatives look promising, but there are other, better reasons to hold the stock through the next 20 years. Over the next decade, the company should ride the wave of the rapidly growing weight-loss market, where it is the leader. Even after it loses patent exclusivity for some of its current growth drivers, Eli Lilly should be fine. The company has improved its pipeline through internal development and acquisitions and boasts promising products across a broad range of therapeutic areas, including neuroscience, immunology, and oncology. Over the next five years, the company should make significant clinical progress in these fields, and by the time medicines such as Zepbound and Mounjaro lose patent exclusivity -- which won't be anytime soon -- Eli Lilly will be ready. In other words, Eli Lilly has strong innovative capabilities that allow it to overcome patent cliffs and competition. That's an important reason it can deliver outstanding returns through the next two decades, especially as its AI efforts might help boost its already strong innovative capabilities. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $464,439 !* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,150,455 !* Now, it’s worth noting Stock Advisor’s total average return is 949 % — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of January 26, 2026. Prosper Junior Bakiny has positions in Eli Lilly and Nvidia. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags Markets The Motley Fool Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. Visit Fool.com for more market news -> More articles by this source -> Stocks mentioned LLY More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.